Melphalan Flufenamide

Melphalan Flufenamide

SCHEMBL20208719

CCOC(=O)C(Cc1ccc(F)cc1)NC(=O)[C@@H](N)Cc1ccc(N(CCCl)CCCl)cc1

nearest known ligand 0.53

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.53
▸ CYP3A4 P08684 3/20 0.52
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ KMT2A Q03164 3/20 0.52
▸ ALDH1A1 P00352 2/20 0.52
▸ ALOX15 P16050 2/20 0.52
▸ HIF1A Q16665 2/20 0.52
▸ MEN1 O00255 2/20 0.52
▸ ABCB11 O95342 1/20 0.52
▸ CHRM2 P08172 1/20 0.52
▸ ADRA2A P08913 1/20 0.52
▸ CHRM1 P11229 1/20 0.52
▸ ACHE P22303 1/20 0.52
▸ PTGS1 P23219 1/20 0.52
▸ OPRM1 P35372 1/20 0.52
▸ DRD3 P35462 1/20 0.52
▸ SLC6A3 Q01959 1/20 0.52
▸ KCNH2 Q12809 1/20 0.52
▸ TDP1 Q9NUW8 1/20 0.52
▸ CYP1A2 P05177 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Melphalan Flufenamide SCHEMBL18239898 1.00 LMNA (0.53) LMNACYP3A4SMN1; SMN2KMT2AALDH1A1
Melphalan Flufenamide SCHEMBL24101233 1.00 LMNA (0.53) LMNACYP3A4SMN1; SMN2KMT2AALDH1A1
Melphalan Flufenamide SCHEMBL29375249 0.99 LMNA (0.52) LMNACYP3A4SMN1; SMN2KMT2AALDH1A1
SCHEMBL24251989 0.92 LMNA (0.47) LMNACYP3A4SMN1; SMN2KMT2AALDH1A1
SCHEMBL6838403 0.92 LMNA (0.47) LMNACYP3A4SMN1; SMN2KMT2AALDH1A1
SCHEMBL10653540 0.92 LMNA (0.47) LMNACYP3A4SMN1; SMN2KMT2AALDH1A1
SCHEMBL24100557 0.91 LMNA (0.44) LMNACYP3A4SMN1; SMN2KMT2AALDH1A1
SCHEMBL25022336 0.91 LMNA (0.43) LMNACYP3A4SMN1; SMN2KMT2AALDH1A1
SCHEMBL22240387 0.89 LMNA (0.51) LMNACYP3A4SMN1; SMN2KMT2AALDH1A1
SCHEMBL25022665 0.88 LMNA (0.40) LMNACYP3A4SMN1; SMN2KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3280721-B1 PROCESS FOR PREPARATION OF NITROGEN MUSTARD DERIVATIVES ONCOPEPTIDES AB (SE) 2020-07-22 — — EP disclosed
US-10287316-B2 Process for preparation of nitrogen mustard derivatives ONCOPEPTIDES AB (SE) 2019-05-14 — — US disclosed
US-20180148473-A1 PROCESS FOR PREPARATION OF NITROGEN MUSTARD DERIVATIVES ONCOPEPTIDES AB (SE) 2018-05-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148473-A1 PROCESS FOR PREPARATION OF NITROGEN MUSTARD DERIVATIVES CBR3, GRHPR, CTH LMNA 2888/4885CYP3A4 205/4885SMN1; SMN2 4220/4885
US-10287316-B2 Process for preparation of nitrogen mustard derivatives CBR3, GRHPR, CTH LMNA 2888/4885CYP3A4 205/4885SMN1; SMN2 4220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback